在心力衰竭中使用SGLT2抑制剂的悖论:对药物向药物的谨慎使用 门德尔随机化
Haozhang Huang1, Huangtao Ruan1, Jin Liu1
1Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 510080, China; Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.
European journal of pharmacology
|July 18, 2025
概括
使用SLC5A2遗传变异的门德尔随机化 (MR) 发现,增加的-葡萄糖共运输体-2抑制剂 (SGLT2i) 活性与心力衰竭风险降低有关. 该研究强调了强大的仪器变量和药物向MR分析中的正控的重要性.
科学领域:
- 流行病学研究 流行病学研究
- 遗传流行病学遗传流行病学
- 药物基因组学 药物基因组学
背景情况:
- 门德尔随机化 (MR) 是流行病学中因果推理的强大工具.
- 在将MR应用于药物标方面仍然存在挑战,特别是在仪器变量 (IV) 选择和正控方面.
- -葡萄糖共传输体-2 抑制剂 (SGLT2i) 是一种针对 SLC5A2 的药物,已知与心血管结果相关.
研究的目的:
- 使用MR检测SGLT2i目标 (SLC5A2基因变异) 与心力衰竭 (HF) 之间的关联.
- 评估不同IV选择策略对药物标MR结果的影响.
- 强调正控在验证药物标MR分析中的关键作用.
主要方法:
- 采用了基于总结数据的MR和逆方差加权 (IVW) -MR分析.
- 针对SLC5A2,利用了各种IV组,包括基于mRNA表达和在所有组织中显著的单核酸多态 (SNPs) 的IV组.
- 评估了与2型糖尿病 (T2D) 和肝炎的关联,并评估了积极对照的有效性.
主要成果:
- 最初的MR分析显示,SLC5A2表达与HF之间没有显著的关联,但与T2D有显著的关联.
- 使用不同的静脉注射组进行的IVW-MR分析显示,SLC5A2介导的HbA1c与T2D和HF之间存在显著的关联.
- 在所有组织中使用mRNA表达和顶部SNP衍生的IV分析始终显示SLC5A2活性和HF风险之间存在显著的反向关联.
结论:
- 这项研究提供了证据,支持SGLT2抑制与心力衰竭风险之间的潜在保护性关联.
- 强调需要仔细选择仪器变量,并在药物向MR研究中使用正对照.
- 敦促研究人员报告IVs,了解药理机制,呈现阳性对照结果,并谨慎解释发现.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
511
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511
01:30Heart Failure V: Medical Management
26
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
26
01:26Heart Failure Drugs: Inotropic Agents
732
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
732
01:22Heart Failure Drugs: Diuretics
495
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
495
01:29Heart Failure II: Pathophysiology
45
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
45
01:22Heart Failure Drugs: β-Blockers
435
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
435